CURR Cure Pharmaceutical Holding

United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens.

Recognizing escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population.

“CURE was founded on the principles of affordability and global accessibility of medications,” said Rob Davidson, CEO of Cure Pharmaceutical.  “We are driven to finding healthcare solutions for people of all ages and demographics and we are honored to be in service to this cause with United Smart Cities. Our mutual goal is to invigorate health and elevate living standards through education and sustainable new technologies.”

“We are happy to add CURE Pharmaceutical into United Smart Cities’ private sector partnership pool,” said Kari Eik, United Smart Cities Co-Director, and Secretary General of OiER. “Health infrastructure is a key focus area for the United Smart Cities program, and we look forward to engaging with health solution providers from diverse sectors to jointly contribute to the development of robust, sustainable health infrastructure for smart sustainable cities worldwide.”

About CURE Pharmaceutical



CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.



For more information about CURE Pharmaceutical, please visit its website at

About United Smart Cities

The United Smart Cities program is a global multi-stakeholder initiative, established by the Organization for International Economic Relations (OiER) in cooperation with the United Nations Economic Commission for Europe (UNECE) and other international organizations, cities, industry and finance sector. It is a unique platform that brings together international organizations, companies, governments and high-level decision makers to work together on one Goal: To support cities to become smarter and more sustainable and implement priority projects towards the achievement of the SDGs at the local level.

The aim of the United Smart Cities program is to evaluate cities’ performances and set priorities for action, develop analysis of cities (city profiles), support strategies in terms of urban planning and priorities (action plan), project development, finance options, and investors’ engagement in cooperation with urban experts and the private sector.

For more information about United Smart Cities, please visit

Media Inquiries:

Ashley Ray

310.824.9000

EN
09/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cure Pharmaceutical Holding

 PRESS RELEASE

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased...

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022. Key operational highlights included the following: Gross revenue of $1.6 million reflected an increase of 31.2% from Q1 to Q2 with f...

 PRESS RELEASE

CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Boar...

CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience. Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success in closing multi-bi...

 PRESS RELEASE

CURE Pharmaceutical Provided Full Corporate Update on Recent Sharehold...

CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update. As discussed on the call, the Company intends to execute on its strat...

 PRESS RELEASE

CURE Pharmaceutical Announces the Appointment of New Board Member

CURE Pharmaceutical Announces the Appointment of New Board Member Gerald Bagg brings deep understanding of CPG to CURE OXNARD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. “With the increased prominence of CURE’s wholly-owned subsidiary, The Sera Labs, Inc., and the efforts we are undertaking to grow existing brands as well as develo...

 PRESS RELEASE

CURE Pharmaceutical Announces Teleconference With Investors

CURE Pharmaceutical Announces Teleconference With Investors Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a teleconference with management on Wednesday, August 3, 2022, at 5:00 pm Eastern Time to discuss the recent $20 million non-dilutive sale of a small portion of its product and intellectual property portfolio and to provide a business update. As a business update we would like to note the fol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch